<DOC>
	<DOCNO>NCT01576861</DOCNO>
	<brief_summary>After encourage result 6 month Growth Hormone Replacement Therapy Patients With Chronic Heart Failure Coexisting Growth Hormone Deficiency ( NCT00591760 ) investigator want collect data long-term efficacy safety kind therapy .</brief_summary>
	<brief_title>Long-Term Efficacy Safety Growth Hormone Replacement Therapy Chronic Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Dwarfism , Pituitary</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Chronic Heart Failure New York Heart Association functional class II IV , secondary ischemic idiopathic cardiomyopathy Age range 1880 year Stable medication least one month include betablockers start least 5 month enter study Left Ventricular ejection fraction 40 % less Growth Hormone Deficiency ( define peak GH response intravenous stimulation GHRH + Arginine &lt; 9 ng/ml ) Written Informed consent Acute proliferative severe nonproliferative diabetic retinopathy Active malignancy Evidence progression recurrence underlie intracranial tumor Unstable Angina recent myocardial infarction Serum Creatinine level &gt; 2.5 mg/dl Severe liver disease ( ChildPugh BC )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2012</verification_date>
</DOC>